Андреев Д.Н., Заборовский А.В., Трухманов А.С., Маев И.В., Ивашкин В.Т. Эволюция представлений о функциональных заболеваниях желудочнокишечного тракта в свете Римских критериев IV пересмотра (2016 г.). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(1):4-11. Режим доступа: https://www.gastro-j.ru/jour/articLe/view/117/92.https://www.gastro-j.ru/jour/articLe/view/117/92
Андреев Д.Н., Заборовский А.В., Трухманов А.С., Маев И.В., Ивашкин В.Т. Эволюция представлений о функциональных заболеваниях желудочнокишечного тракта в свете Римских критериев IV пересмотра (2016 г.). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(1):4-11. Режим доступа: https://www.gastro-j.ru/jour/articLe/view/117/92.https://www.gastro-j.ru/jour/article/view/117/92
Drossman D.A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016. pii: S0016-5085(16)00223-7. doi: 10.1053/j.gastro.2016.02.032..
DOI: 10.1053/j.gastro.2016.02.032
Drossman D.A., HasLer W.L. Rome IV-FunctionaL GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257-1261. doi: 10.1053/j.gastro.2016.03.035..
DOI: 10.1053/j.gastro.2016.03.035
Андреев Д.Н. Роль нарушения проницаемости слизистой оболочки кишечника в генезе функциональных заболеваний желудочно-кишечного тракта. Consilium Medicum. 2019;21(8):29-34. Режим доступа: https://consiLium.orscience.ru/upLoad/ibLock/aa4/aa4fbaedab4bd8eb2829dfcd57cb5343.pdf.https://consiLium.orscience.ru/upLoad/ibLock/aa4/aa4fbaedab4bd8eb2829dfcd57cb5343.pdf
Андреев Д.Н. Роль нарушения проницаемости слизистой оболочки кишечника в генезе функциональных заболеваний желудочно-кишечного тракта. Consilium Medicum. 2019;21(8):29-34. Режим доступа: https://consiLium.orscience.ru/upLoad/ibLock/aa4/aa4fbaedab4bd8eb2829dfcd57cb5343.pdf.https://consilium.orsci-ence.ru/upload/iblock/aa4/aa4fbaedab4bd8eb2829dfcd57cb5343.pdf
de BortoLi N., ToLone S., Frazzoni M., Martinucci I., Sgherri G., ALbano E. et aL. GastroesophageaL refLux disease, functionaL dyspepsia and irritabLe boweL syndrome: common overLapping gastrointestinaL disorders. Ann Gastroenterol. 2018;31(6):639-648. doi: 10.20524/aog.2018.0314..
DOI: 10.20524/aog.2018.0314
Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Функциональная диспепсия. М.: Ремедиум; 2019. 60 с.
Маев И.В., Черемушкин С.В., Кучерявый ЮА. Андреев Д.Н. Синдром раздраженного кишечника с позиций современной фундаментальной и клинической медицины. М.: Прима Принт; 2019. 96 с. Режим доступа: http://zakofaLk.ru/fiLes/7f423324339580d26bdec969712f2c971581082159.pdf.http://zakofaLk.ru/fiLes/7f423324339580d26bdec969712f2c971581082159.pdf
Маев И.В., Черемушкин С.В., Кучерявый ЮА. Андреев Д.Н. Синдром раздраженного кишечника с позиций современной фундаментальной и клинической медицины. М.: Прима Принт; 2019. 96 с. Режим доступа: http://zakofaLk.ru/fiLes/7f423324339580d26bdec969712f2c971581082159.pdf.http://zakofalk.ru/files/7f423324339580d26bdec969712f2c971581082159.pdf
Mahadeva S., Goh K.L. EpidemioLogy of functionaL dyspepsia: a gLobaL perspective. World J Gastroenterol. 2006;12(17):2661-2666. AvaiLabLe at: https://www.ncbi.nLm.nih.gov/pubmed/16718749.https://www.ncbi.nLm.nih.gov/pubmed/16718749
Mahadeva S., Goh K.L. EpidemioLogy of functionaL dyspepsia: a gLobaL perspective. World J Gastroenterol. 2006;12(17):2661-2666. AvaiLabLe at: https://www.ncbi.nLm.nih.gov/pubmed/16718749.https://www.ncbi.nlm.nih.gov/pubmed/16718749
Canavan C., West J., Card T. The epidemioLogy of irritabLe boweL syndrome. Clin Epidemiol. 2014;6:71-80. doi: 10.2147/CLEPS40245..
DOI: 10.2147/CLEPS40245
Oshima T., Miwa H. EpidemioLogy of FunctionaL GastrointestinaL Disorders in Japan and in the WorLd. J Neurogastroenterol Motil. 2015;21(3):320-329. doi: 10.5056/jnm14165..
DOI: 10.5056/jnm14165
Дичева Д.Т., Андреев Д.Н., Ульянкина Е.В. Синдром перекреста ГЭРБ, функциональной диспепсии и СРК: патогенетические связи и подходы к терапии. Эффективная фармакотерапия. 2019;15(36):64-70. Режим доступа: https://www.gastroscan.ru/Literature/authors/11650.https://www.gastroscan.ru/Literature/authors/11650
Дичева Д.Т., Андреев Д.Н., Ульянкина Е.В. Синдром перекреста ГЭРБ, функциональной диспепсии и СРК: патогенетические связи и подходы к терапии. Эффективная фармакотерапия. 2019;15(36):64-70. Режим доступа: https://www.gastroscan.ru/Literature/authors/11650.https://Www.gastroscan.ru/literature/authors/11650
von WuLffen M., TaLLey NJ., Hammer J., McMaster J., Rich G., Shah A. et aL. OverLap of IrritabLe BoweL Syndrome and FunctionaL Dyspepsia in the CLinicaL Setting: PrevaLence and Risk Factors. Dig Dis Sci. 2019;64(2):480-486. doi: 10.1007/s10620-018-5343-6..
DOI: 10.1007/s10620-018-5343-6
Ford A.C., Marwaha A., Lim A., Moayyedi P Systematic review and metaanaLysis of the prevaLence of irritabLe boweL syndrome in individuaLs with dyspepsia. Clin Gastroenterol Hepatol. 2010;8(5):401-419. doi: 10.1016/j.cgh.2009.07.020..
DOI: 10.1016/j.cgh.2009.07.020
Ford A.C., Forman D., BaiLey A.G., Axon A.T., Moayyedi P. IrritabLe boweL syndrome: a 10-yr naturaL history of symptoms and factors that infLuence consuLtation behavior. Am J Gastroenterol. 2008;103(5):1229-1239. doi: 10.1111/j.1572-0241.2007.01740.x..
DOI: 10.1111/j.1572-0241.2007.01740.x
HaLder S.L., Locke G.R., SchLeck C.D., Zinsmeister A.R., MeLton LJ., TaLLey NJ. NaturaL history of functionaL gastrointestinaL disorders: a 12-year LongitudinaL popuLation-based study. Gastroenterology 2007;133(3):799-807. doi: 10.1053/j.gastro.2007.06.010..
DOI: 10.1053/j.gastro.2007.06.010
Lee HJ., Lee S.Y, Kim J.H., Sung I.K., Park H.S., Jin CJ. et aL. Depressive mood and quaLity of Life in functionaL gastrointestinaL disorders: differences between functionaL dyspepsia, irritabLe boweL syndrome and overLap syndrome. Gen Hosp Psychiatry. 2010;32(5):499-502. doi: 10.1016/j.genhosppsych.2010.05.002..
DOI: 10.1016/j.genhosppsych.2010.05.002
Андреев Д.Н., Дичева Д.Т. Оптимизация лечения пациентов с синдромом раздраженного кишечника: фокус на повышение комплаентно-сти. Медицинский совет. 2019;(3):118-124. doi: 10.21518/2079-701X-2019-3-118-124..
DOI: 10.21518/2079-701X-2019-3-118-124
Choung R.S. NaturaL history and overLap of functionaL gastrointestinaL disorders. Korean J Gastroenterol. 2012;60(6):345-348. doi: 10.4166/kjg.2012.60.6.345..
DOI: 10.4166/kjg.2012.60.6.345
Keita A.V., SoderhoLm J.D. MucosaL permeabiLity and mast ceLLs as targets for functionaL gastrointestinaL disorders. Curr Opin Pharmacol. 2018;43:66-71. doi: 10.1016/j.coph.2018.08.011..
DOI: 10.1016/j.coph.2018.08.011
Farre R., Vicario M. AbnormaL Barrier Function in GastrointestinaL Disorders. Handb Exp Pharmacol. 2017;239:193-217. doi: 10.1007/164_2016_107..
DOI: 10.1007/164_2016_107
Bevins C.L., SaLzman N.H. Paneth ceLLs, antimicrobiaL peptides and maintenance of intestinaL homeostasis. Nat Rev Microbiol. 2011;9(5):356-368. doi: 10.1038/nrmicro2546..
DOI: 10.1038/nrmicro2546
Zihni C., MiLLs C., Matter K., BaLda M.S. Tight junctions: from simpLe barriers to muLtifunctionaL moLecuLar gates. Nat Rev Mol Cell Biol. 2016;17(9):564-580. doi: 10.1038/nrm.2016.80..
DOI: 10.1038/nrm.2016.80
Piche T. Tight junctions and IBS - the Link between epitheLiaL permeabiLity, Low-grade infLammation, and symptom generation? Neurogastroenterol Motil. 2014;26(3):296-302. doi: 10.1111/nmo.12315..
DOI: 10.1111/nmo.12315
Bischoff S.C., Barbara G., Buurman W., Ockhuizen T., SchuLzke J.D., Serino M. et aL. IntestinaL permeabiLity - a new target for disease prevention and therapy. BMC Gastroenterol. 2014;14:189. doi: 10.1186/s12876-014-0189-7..
DOI: 10.1186/s12876-014-0189-7
Morris G., Berk M., CarvaLho A.F., Caso J.R., Sanz Y., Maes M. The RoLe of Microbiota and IntestinaL PermeabiLity in the PathophysioLogy of Autoimmune and Neuroimmune Processes with an Emphasis on InfLammatory BoweL Disease Type 1 Diabetes and Chronic Fatigue Syndrome. Curr Pharm Des. 2016;22(40):6058-6075. doi: 10.2174/1381612822666160914182822..
DOI: 10.2174/1381612822666160914182822
Kerckhoffs A.P., Akkermans L.M., de Smet M.B., BesseLink M.G., Hietbrink F., BarteLink I.H. et aL. IntestinaL permeabiLity in irritabLe boweL syndrome patients: effects of NSAIDs. Dig Dis Sci. 2010;55(3):716-723. doi: 10.1007/s10620-009-0765-9..
DOI: 10.1007/s10620-009-0765-9
VanuytseL T., van Wanrooy S., VanheeL H., VanormeLingen C., Verschueren S., Houben E. et aL. PsychoLogicaL stress and corticotropin-reLeasing hormone increase intestinaL permeabiLity in humans by a mast ceLL-dependent mechanism. Gut. 2014;63(8):1293-1299. doi: 10.1136/gutjnL-2013-305690..
DOI: 10.1136/gutjnL-2013-305690
VanuytseL T., van Wanrooy S., VanheeL H., VanormeLingen C., Verschueren S., Houben E. et aL. PsychoLogicaL stress and corticotropin-reLeasing hormone increase intestinaL permeabiLity in humans by a mast ceLL-dependent mechanism. Gut. 2014;63(8):1293-1299. doi: 10.1136/gutjnL-2013-305690..
DOI: 10.1136/gutjnl-2013-305690
Hammer A.M., Morris N.L., EarLey Z.M., Choudhry M.A. The First Line of Defense: The Effects of ALcohoL on Post-Burn IntestinaL Barrier, Immune CeLLs, and Microbiome. Alcohol Res. 2015;37(2):209-222. AvaiLabLe at: https://www.ncbi.nLm.nih.gov/pubmed/26695746.https://www.ncbi.nLm.nih.gov/pubmed/26695746
Hammer A.M., Morris N.L., EarLey Z.M., Choudhry M.A. The First Line of Defense: The Effects of ALcohoL on Post-Burn IntestinaL Barrier, Immune CeLLs, and Microbiome. Alcohol Res. 2015;37(2):209-222. AvaiLabLe at: https://www.ncbi.nLm.nih.gov/pubmed/26695746.https://www.ncbi.nlm.nih.gov/pubmed/26695746
Park M.Y, Kim M.Y., Seo Y.R., Kim J.S., Sung M.K. High-fat Diet AcceLerates IntestinaL Tumorigenesis Through Disrupting IntestinaL CeLL Membrane Integrity. J Cancer Prev. 2016;21(2):95-103. doi: 10.15430/JCP2016.21.2.95..
DOI: 10.15430/JCP2016.21.2.95
Du L., Shen J., Kim JJ., He H., Chen B., Dai N. Impact of gluten consumption in patients with functional dyspepsia: A case-control study. J Gastroenterol Hepatol. 2018;33(1):128-133. doi: 10.1111/jgh.13813..
DOI: 10.1111/jgh.13813
Camilleri M., Oduyebo I., Halawi H. Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions. Am J Physiol Gastrointest Liver Physiol. 2016;311(5):777-784. doi: 10.1152/ajpgi.00242.2016..
DOI: 10.1152/ajpgi.00242.2016
Ng Q.X., Soh A.Y.S., Loke W., Lim D.Y., Yeo W.S. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res. 2018;11:345-349. doi: 10.214/JIR.S174982..
DOI: 10.214/JIR.S174982
Самсонов АА., Андреев Д.Н., Дичева Д.Т. Синдром раздраженного кишечника с позиций современной гастроэнтерологии. Фарматека. 2014;(18):7-14. Режим доступа: https://www.elibrary.ru/item.asp?id=22474321.https://www.elibrary.ru/item.asp?id=22474321
Самсонов АА., Андреев Д.Н., Дичева Д.Т. Синдром раздраженного кишечника с позиций современной гастроэнтерологии. Фарматека. 2014;(18):7-14. Режим доступа: https://www.elibrary.ru/item.asp?id=22474321.https://www.elibrary.ru/item
Niessen C.M. Tight junctions/adherens junctions: basic structure and function. J Invest Dermatol. 2007;127(11):2525-2532. doi: 10.1038/sj.jid.5700865..
DOI: 10.1038/sj.jid.5700865
Hartsock A., Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta. 2008;1778(3):660-669. doi: 10.1016/j.bbamem.2007.07.012..
DOI: 10.1016/j.bbamem.2007.07.012
Piche T., Barbara G., Aubert P, Bruley des Varannes S., Dainese R., Nano J.L et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut. 2009;58(2):196-201. doi: 10.1136/gut.2007.140806..
DOI: 10.1136/gut.2007.140806
Coeffier M., Gloro R., Boukhettala N., Aziz M., Lecleire S., Vandaele N. et al. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol. 2010;105(5):1181-1188. doi: 10.1038/ajg.2009.700..
DOI: 10.1038/ajg.2009.700
Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G. et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol. 2011;106(12):2165-2173. doi: 10.1038/ajg.2011.257..
DOI: 10.1038/ajg.2011.257
Martinez C., Vicario M., Ramos L., Lobo B., Mosquera J.L., Alonso C. et al. The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol. 2012;107(5):736-746. doi: 10.1038/ajg.2011.472..
DOI: 10.1038/ajg.2011.472
Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C. et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut. 2013;62(8):1160-1168. doi: 10.1136/gutjnl-2012-302093..
DOI: 10.1136/gutjnl-2012-302093
Vanheel H., Vicario M., Vanuytsel T., Van Oudenhove L., Martinez C., Keita A.V. et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014;63(2):262-271. doi: 10.1136/gutjnl-2012-303857..
DOI: 10.1136/gutjnl-2012-303857
Lee K.N., Lee O.Y. The Role of Mast Cells in Irritable Bowel Syndrome. Gastroenterol Res Pract. 2016;2016:2031480. doi: 10.1155/2016/2031480..
DOI: 10.1155/2016/2031480
Buhner S., Li O., Vignali S., De Giorgio R., Stanghellini V., Cremon C. et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology. 2009;137(4):1425-1434. doi: 10.1053/j.gastro.2009.07.005..
DOI: 10.1053/j.gastro.2009.07.005
Barbara G., Wang B., Stanghellini V., de Giorgio R., Cremon C., Di Nardo G. et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132(1):26-37. doi: 10.1053/j.gastro.2006.11.039..
DOI: 10.1053/j.gastro.2006.11.039
Du L., Chen B., Kim JJ., Chen X., Dai N. Micro-inflammation in functional dyspepsia: A systematic review and meta-analysis. Neurogastroenterol Motil. 2018;30(4):e13304. doi: 10.1111/nmo.13304..
DOI: 10.1111/nmo.13304
Bashashati M., Moossavi S., Cremon C., Barbaro M.R., Moraveji S., Talmon G. et al. Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil. 2018;30(1). doi: 10.1111/nmo.13192..
DOI: 10.1111/nmo.13192
Camilleri M., Bueno L., Andresen V., De Ponti F., Choi M.G., Lembo A. Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders. Gastroenterology. 2016. pii: S0016-5085(16)00220-1. doi: 10.1053/j.gastro.2016.02.029..
DOI: 10.1053/j.gastro.2016.02.029
Leech B., Schloss J., Steel A. Treatment Interventions for the Management of Intestinal Permeability: A Cross-Sectional Survey of Complementary and Integrative Medicine Practitioners. J Altern Complement Med. 2019;25(6):623-636. doi: 10.1089/acm.2018.0374..
DOI: 10.1089/acm.2018.0374
Leech B., McIntyre E., Steel A., Sibbritt D. Risk factors associated with intestinal permeability in an adult population: A systematic review. Int J Clin Pract. 2019;73(10):e13385. doi: 10.1111/ijcp.13385..
DOI: 10.1111/ijcp.13385
Sturniolo G.C., Fries W., Mazzon E., Di Leo V., Barollo M., D’Inca R. Effect of zinc supplementation on intestinal permeability in experimental colitis. Journal of Laboratory and Clinical Medicine. 2002;139(5):311-315. doi: 10.1067/mlc.2002.123624..
DOI: 10.1067/mlc.2002.123624
Zhou O., Verne M.L., Fields J.Z., Lefante JJ., Basra S., Salameh H., Verne G.N. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019;68(6):996-1002. doi: 10.1136/gutjnl-2017-315136..
DOI: 10.1136/gutjnl-2017-315136
Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-270. doi: 10.1586/egh.10.25..
DOI: 10.1586/egh.10.25
Song D.U., Ryu M.H., Chay K.O., Jung Y.D., Yang S.Y. et al. Effect of rebamipi-de on the glycosaminoglycan content of the ulcerated rat stomach. Fundam Clin Pharmacol. 1998;12(5):546-552. doi: 10.1111/j.1472-8206.1998.tb00984.x..
DOI: 10.1111/j.1472-8206.1998.tb00984.x
Suzuki T., Yoshida N., Nakabe N., Isozaki Y., Kajikawa H., Takagi T. et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008;106(3):469-477. doi: 10.1254/jphs.fp0071422..
DOI: 10.1254/jphs.fp0071422
Tarnawski A.S., Chai J., Pai R., Chiou S.K. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004;49(2):202-209. doi: 10.1023/b:ddas.0000017439.60943.5c..
DOI: 10.1023/b:ddas.0000017439.60943.5c
Jaafar M.H., Safi S.Z., Tan M.P., Rampal S., Mahadeva S. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018;63(5):1250-1260. doi: 10.1007/ s10620-017-4871-9..
DOI: 10.1007/ s10620-017-4871-9
Jaafar M.H., Safi S.Z., Tan M.P., Rampal S., Mahadeva S. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018;63(5):1250-1260. doi: 10.1007/ s10620-017-4871-9..
DOI: 10.1007/s10620-017-4871-9
Matysiak-Budnik T., Heyman M., Megraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18(Suppl 1):55-62. doi: 10.1046/j.1365-2036.18.s1.6.x..
DOI: 10.1046/j.1365-2036.18.s1.6.x
Hayashi S., Sugiyama T., Amano K., Isogai H., Isogai E., Aihara M. et al. Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother. 1998;42(8):1895-1899. Режим доступа: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC105706/.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC105706/
Hayashi S., Sugiyama T., Amano K., Isogai H., Isogai E., Aihara M. et al. Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother. 1998;42(8):1895-1899. Режим доступа: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC105706/.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC105706/
Andreev D.N., Maev I.V., Dicheva D.T. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med. 2019;8(9). pii: E1498. doi: 10.3390/jcm8091498..
DOI: 10.3390/jcm8091498
Pittayanon R., Leelakusolvong S., Vilaichone R.K., Rojborwonwitaya J., Treeprasertsuk S., Mairiang P. et al. Thailand Dyspepsia Guidelines: 2018. J Neurogastroenterol Motil. 2019;25(1):15-26. doi: 10.5056/jnm18081..
DOI: 10.5056/jnm18081